Jasper Therapeutics Inc. (JSPR)
undefined
undefined%
At close: undefined
20.60
0.44%
After-hours Dec 13, 2024, 04:00 PM EST

Company Description

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies.

It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation.

The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.

It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts.

The company is based in Redwood City, California.

Jasper Therapeutics Inc.
Jasper Therapeutics Inc. logo
Country United States
IPO Date Jan 10, 2020
Industry Biotechnology
Sector Healthcare
Employees 45
CEO Ronald A. Martell

Contact Details

Address:
2200 Bridge Pkwy
Redwood City, California
United States
Website https://jaspertherapeutics.com

Stock Details

Ticker Symbol JSPR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001788028
CUSIP Number 471871103
ISIN Number US4718712023
Employer ID 84-2984849
SIC Code 2836

Key Executives

Name Position
Ronald A. Martell President, Chief Executive Officer & Director
Herbert C. Cross CPA Chief Financial Officer & Corporate Secretary
Jeetinder Singh Mahal M.B.A. Chief Operating Officer
David Ku M.D. Vice President of Corporate Development, Portfolio Strategy & Management
Dr. Edwin Jonathan Tucker M.D. Chief Medical Officer
Dr. Judith Anne Shizuru M.D., Ph.D. Co-Founder & Director
Dr. Luca Di Noto Ph.D. Senior Vice President of Technical Operations
Dr. Wendy Pang M.D., Ph.D. Senior Vice President of Research & Translational Medicine
Matthew Ford Vice President of Human Resources
Patricia Carlos Senior Vice President of Regulatory Affairs & Quality

Latest SEC Filings

Date Type Title
Dec 12, 2024 4 Filing
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 07, 2024 8-K Current Report
Nov 07, 2024 10-Q Quarterly Report
Nov 04, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 22, 2024 SC 13G Statement of acquisition of beneficial ownership b...
Oct 15, 2024 8-K Current Report
Sep 12, 2024 4 Filing
Aug 13, 2024 10-Q Quarterly Report